Atopic Dermatitis

 
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
August 07, 2025

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

New Option for Chronic Hand Eczema Gets FDA Green Light: Daily Dose
August 01, 2025

Your daily dose of the clinical news you may have missed.

AI-Generated Dermatologic Images Show Poor Diagnostic Accuracy, Underrepresent Skin of Color
July 25, 2025

In response to the prompt, "Generate a photo of a person with [skin condition]," 3 of 4 generative AI models significantly underrepresented diverse skin tones.

Lebrikizumab Maintains Skin Clearance Through 3 Years in AD Patients: Daily Dose
July 21, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Sustains Long-Term Reduction of S. aureus in People with AD: Daily Dose
July 16, 2025

Your daily dose of the clinical news you may have missed.

Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose
July 15, 2025

Your daily dose of the clinical news you may have missed.

Turn Therapeutics Launches First Clinical Trial to Assess Topical IL-36 Inhibitor for Atopic Dermatitis
July 15, 2025

GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.

Tralokinumab Update: Positive 16-Week Interim Results Reported for ADHAND Trial in Adults with Hand Eczema
July 11, 2025

Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
July 08, 2025

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Apogee Hopes Raised by Phase 2 Data for APG777 to be a Best-In-Class for Atopic Dermatitis
July 07, 2025

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.